Gufic Biosciences cleared to invest US$780.9K in Saraswat Co-operative Bank
What's the deal? Indian pharmaceutical company Gufic Biosciences has received board approval to invest US$780.9K (roughly $680K) in the equity share capital of Saraswat Co-operative Bank. The company will subscribe to 5.75 million new equity shares at a face value of US$0.14 each.
The board approved the investment at its meeting on May 29, 2026. Gufic Biosciences already uses Saraswat Bank for various banking and credit facilities tied to its business operations.
Why now? The investment aligns with Gufic's existing banking relationship and credit exposure. The company said it expects the move to strengthen its ties with the bank while also serving its broader treasury management strategy.
Gufic pointed to potential long-term benefits including investment appreciation, dividend income, and improved banking engagement.
What could go wrong? Co-operative banks in India have faced governance and asset-quality challenges in the past, making equity investments in them inherently riskier than in listed commercial banks. The shares are unlikely to be liquid, which could make exiting the position difficult.
At US$780.9K, the investment is modest relative to Gufic's market capitalisation of US$466.8M — but even small treasury bets can draw scrutiny if they sour.
The signal: Gufic Biosciences is a mature pharmaceutical company specialising in lyophilised products and critical care medicines for major Indian hospital chains. Its decision to deepen ties with a co-operative lender through a modest equity stake — rather than pursue a more conventional treasury allocation — underscores how mid-cap Indian pharma firms still rely heavily on relationship banking to support operational credit lines and expansion financing.
Read more: investmentguruindia.com
